Cite this article
Volume | Year
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Alteration of serum endocan in normal pregnancy and preeclampsia
1 Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Key Laboratory of Reproductive Genetics, Ministry of Education, Hangzhou, China
2 Key Laboratory of Women's Reproductive Health of Zhejiang Province, Hangzhou, China
Clin. Exp. Obstet. Gynecol. 2017, 44(3), 419–422; https://doi.org/10.12891/ceog3452.2017
Published: 10 June 2017
Endocan is a novel marker for inflammation but its significance in preeclampsia remains unknown. Objective: The aims of this study were to delineate the changes of maternal endocan in normal pregnancy and preeclampsia and to explore its possible role in the pathogenesis of preeclampsia. Materials and Methods: Blood samples were taken from 42 non-pregnant women, from 43 normal pregnant women at third trimester, and from 41 preeclamptic women. Serum endocan levels were determined with enzyme-linked immunosorbent assay (ELISA) and compared among the groups. Results: There were no significant differences in serum endocan among non-pregnant women, normal pregnant women, and women with preeclampsia (χ2= 2.207, p = 0.137) and there was no significant difference in serum endocan between women with mild and severe preeclampsia (Z = 0.368, p = 0. 713). The authors concluded that serum endocan did not change in pregnancy and preeclampsia, indicating endocan may not be involved in the pathogenesis of preeclampsia.